MiMedx Group Inc.

MDXG

Held by 1 specialist biotech fund

Share on X

Fund Holdings

Deerfield Management

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

Deerfield ManagementNEWFeb 17, 2026

Shares: 160,419Value: $1.1M

# Signal Note: Deerfield Initiates MDXG Position Deerfield Management's $1.1M entry into MiMedx suggests confidence in the company's regenerative medicine portfolio, particularly its placental tissue-derived products (EpiFix, AmnioFix) used in wound care and orthopedic applications. The timing may reflect conviction in upcoming clinical data, reimbursement developments, or potential M&A activity in the allograft biologics space, which has seen recent consolidation. Monitor Q3/Q4 2024 for material announcements on expanded Medicare coverage, clinical outcomes, or strategic partnerships that would validate this thesis.

More MDXG Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

RDNT1 fund VTR1 fund PHVS1 fund PMVP1 fund ALHC1 fund ATRC1 fund BCRX1 fund NBIX

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief: